Radiotherapy for brain tumors.

M. P. Mehta, Wolfgang A. Tome, G. H. Olivera

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Over the last 2 years, several advances have been made in the field of radiotherapy for brain tumors. Key advances are summarized in this review. Crucial technologic advances, such as radiosurgery, fractionated stereotactic radiotherapy, and intensity-modulated radiotherapy, are discussed. Better understanding of the interaction between the processes of angiogenesis, apoptosis, cell-cycle regulation, and signal transduction and the effects of ionizing radiation has made it clear that many of these "new agents" are, in fact, valuable modulators of the radiation response. Another exciting molecular discovery is the recognition of radiation-induced promoters that can be exploited to cause spatially and temporally configured expression of selected genes; this approach may represent the ideal application of conformal radiation techniques in the future, yielding well-defined genetic changes in specifically targeted tissues. The final "frontier" covered in this review is the newer categories of radiosensitizers, ranging from topoisomerase-I inhibitors, to expanded metalloporphyrins, to oxygen- dissociating agents.

Original languageEnglish (US)
Pages (from-to)438-444
Number of pages7
JournalCurrent Oncology Reports
Volume2
Issue number5
StatePublished - Sep 2000
Externally publishedYes

Fingerprint

Brain Neoplasms
Radiotherapy
Radiation
Metalloporphyrins
Topoisomerase I Inhibitors
Intensity-Modulated Radiotherapy
Radiosurgery
Ionizing Radiation
Signal Transduction
Cell Cycle
Apoptosis
Oxygen
Gene Expression

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mehta, M. P., Tome, W. A., & Olivera, G. H. (2000). Radiotherapy for brain tumors. Current Oncology Reports, 2(5), 438-444.

Radiotherapy for brain tumors. / Mehta, M. P.; Tome, Wolfgang A.; Olivera, G. H.

In: Current Oncology Reports, Vol. 2, No. 5, 09.2000, p. 438-444.

Research output: Contribution to journalArticle

Mehta, MP, Tome, WA & Olivera, GH 2000, 'Radiotherapy for brain tumors.', Current Oncology Reports, vol. 2, no. 5, pp. 438-444.
Mehta MP, Tome WA, Olivera GH. Radiotherapy for brain tumors. Current Oncology Reports. 2000 Sep;2(5):438-444.
Mehta, M. P. ; Tome, Wolfgang A. ; Olivera, G. H. / Radiotherapy for brain tumors. In: Current Oncology Reports. 2000 ; Vol. 2, No. 5. pp. 438-444.
@article{7864c23acbc64e62a170c09abd0bca22,
title = "Radiotherapy for brain tumors.",
abstract = "Over the last 2 years, several advances have been made in the field of radiotherapy for brain tumors. Key advances are summarized in this review. Crucial technologic advances, such as radiosurgery, fractionated stereotactic radiotherapy, and intensity-modulated radiotherapy, are discussed. Better understanding of the interaction between the processes of angiogenesis, apoptosis, cell-cycle regulation, and signal transduction and the effects of ionizing radiation has made it clear that many of these {"}new agents{"} are, in fact, valuable modulators of the radiation response. Another exciting molecular discovery is the recognition of radiation-induced promoters that can be exploited to cause spatially and temporally configured expression of selected genes; this approach may represent the ideal application of conformal radiation techniques in the future, yielding well-defined genetic changes in specifically targeted tissues. The final {"}frontier{"} covered in this review is the newer categories of radiosensitizers, ranging from topoisomerase-I inhibitors, to expanded metalloporphyrins, to oxygen- dissociating agents.",
author = "Mehta, {M. P.} and Tome, {Wolfgang A.} and Olivera, {G. H.}",
year = "2000",
month = "9",
language = "English (US)",
volume = "2",
pages = "438--444",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "5",

}

TY - JOUR

T1 - Radiotherapy for brain tumors.

AU - Mehta, M. P.

AU - Tome, Wolfgang A.

AU - Olivera, G. H.

PY - 2000/9

Y1 - 2000/9

N2 - Over the last 2 years, several advances have been made in the field of radiotherapy for brain tumors. Key advances are summarized in this review. Crucial technologic advances, such as radiosurgery, fractionated stereotactic radiotherapy, and intensity-modulated radiotherapy, are discussed. Better understanding of the interaction between the processes of angiogenesis, apoptosis, cell-cycle regulation, and signal transduction and the effects of ionizing radiation has made it clear that many of these "new agents" are, in fact, valuable modulators of the radiation response. Another exciting molecular discovery is the recognition of radiation-induced promoters that can be exploited to cause spatially and temporally configured expression of selected genes; this approach may represent the ideal application of conformal radiation techniques in the future, yielding well-defined genetic changes in specifically targeted tissues. The final "frontier" covered in this review is the newer categories of radiosensitizers, ranging from topoisomerase-I inhibitors, to expanded metalloporphyrins, to oxygen- dissociating agents.

AB - Over the last 2 years, several advances have been made in the field of radiotherapy for brain tumors. Key advances are summarized in this review. Crucial technologic advances, such as radiosurgery, fractionated stereotactic radiotherapy, and intensity-modulated radiotherapy, are discussed. Better understanding of the interaction between the processes of angiogenesis, apoptosis, cell-cycle regulation, and signal transduction and the effects of ionizing radiation has made it clear that many of these "new agents" are, in fact, valuable modulators of the radiation response. Another exciting molecular discovery is the recognition of radiation-induced promoters that can be exploited to cause spatially and temporally configured expression of selected genes; this approach may represent the ideal application of conformal radiation techniques in the future, yielding well-defined genetic changes in specifically targeted tissues. The final "frontier" covered in this review is the newer categories of radiosensitizers, ranging from topoisomerase-I inhibitors, to expanded metalloporphyrins, to oxygen- dissociating agents.

UR - http://www.scopus.com/inward/record.url?scp=0034277708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034277708&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 438

EP - 444

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 5

ER -